Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality

Abstract Background Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is approved for the treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. In pooled analyses of two pivotal phase 3 studies, ASPIRE I and II,...

Full description

Bibliographic Details
Main Authors: Dong-Jing Fu, Qiaoyi Zhang, Ling Shi, Stephane Borentain, Shien Guo, Maju Mathews, Joana Anjo, Abigail I. Nash, Marguerite O’Hara, Carla M. Canuso
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Psychiatry
Subjects:
Esketamine nasal spray
Depressive disorder
Suicidal ideation
Remission
Antidepressant agents
Online Access:https://doi.org/10.1186/s12888-023-05017-y

Internet

https://doi.org/10.1186/s12888-023-05017-y

Similar Items